JAG1 Cancer Research Results

JAG1, Jagged canonical Notch ligand 1: Click to Expand ⟱
Source:
Type:

JAG1 (Jagged canonical Notch ligand 1; Jagged1) is a membrane-bound ligand that activates NOTCH-family receptors on adjacent cells. JAG1–Notch signalling regulates cell fate, differentiation, stem-cell maintenance, angiogenesis and communication between tumour cells and the tumour microenvironment. JAG1 is frequently overexpressed in established cancers and can promote cancer-stem-cell properties, proliferation, epithelial–mesenchymal transition, migration, invasion, angiogenesis, metastasis and resistance to anticancer treatment. JAG1 inhibition or downregulation has reduced tumour-cell growth and invasiveness in several preclinical models. The typical cancer-associated direction is up, while the desired anticancer modulation is generally down or blockade of JAG1–Notch signalling.



Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
7105- GEN,    Effects of genistein supplementation on genome‑wide DNA methylation and gene expression in patients with localized prostate cancer
- Trial, Pca, NA
Risk↓, Myc↓, PTEN↑, Dose↝, NOTCH3↑, JAG1↑, ADCY4↑, NEU1↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ADCY4↑, 1,   JAG1↑, 1,   NEU1↑, 1,  

Cell Death(tgid=5) ⓘ

Myc↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

NOTCH3↑, 1,   PTEN↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

Myc↓, 1,  

Functional Outcomes(tgid=23) ⓘ

Risk↓, 1,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: JAG1, Jagged canonical Notch ligand 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:1579  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page